Rituximab Completed Phase 2 Trials for Lymphoplasmacytic Lymphoma / Waldenström's Macroglobulinemia (WM) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00142116Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
NCT00832234Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia
NCT02400437Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
NCT01470196Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia
NCT00422799Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia
NCT00250926Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia